DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Tendinopathy Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Tendinopathy, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Tendinopathy Market
The market size for Tendinopathy in the 7MM was approximately USD 237.58 million in 2022 and is expected to increase significantly by 2036.
The United States accounted for the highest Tendinopathy market size among the 7MM in 2025, compared to EU4 countries, the United Kingdom, and Japan.
Epidemiological data indicate that 898 per 100,000 individuals in the United States are diagnosed with Achilles tendinopathy, with the highest incidence observed in those aged 50–59 years.
As per secondary research, approximately 4.0% of Achilles tendinopathy patients progressed to rupture, highest in the 50–59 years age group (4.3%).
In the UK, Achilles tendon rupture incidence is 0.008–0.018% per annum, with nearly 4,500 patients seeking medical help yearly.
According to a real-world cohort study, the 12-month prevalence of tendon rupture and tendinopathy was 3.4% among patients with atherosclerotic cardiovascular disease and 1.9% in the overall population.
Leading Tendinopathy companies, such as Causeway Therapeutics and New York R&D Center for Translational Medicine and Therapeutics, are developing novel Tendinopathy therapies that are expected to enter the market in the coming years.
The promising Tendinopathy therapies in development include TenoMiR (CWT-001), TenoGen, and others.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/tendinopathy-market
Key Factors Driving the Tendinopathy Market
Rising Prevalence of Tendon Injuries: Increasing participation in sports, fitness activities, and physically demanding occupations is contributing to a growing burden of tendon injuries and chronic tendinopathy cases globally.
Growing Aging Population: Older adults are particularly susceptible to tendinopathy due to age-related tendon degeneration, reduced healing capacity, and repetitive mechanical stress exposure.
Advancements in Regenerative Medicine: Growing research in biologics, platelet-rich plasma (PRP), extracellular shock wave therapy (ESWT), stem cell therapies, and microRNA-based therapies is reshaping the Tendinopathy treatment landscape.
Increasing Awareness and Improved Diagnosis: Enhanced awareness among healthcare providers and advancements in imaging modalities such as ultrasound and MRI are contributing to earlier and more accurate diagnosis of Tendinopathy.
Tendinopathy Competitive Landscape
Several Tendinopathy therapies are under development, led by Causeway Therapeutics’ TenoMiR (CWT-001), along with TenoGen and other regenerative therapies.
These therapies focus on restoring tendon healing pathways, reducing pain, improving tendon structure, and addressing the underlying degenerative pathology rather than providing only symptomatic relief.
Discover more about therapies set to grab major Tendinopathy market share @ Tendinopathy Treatment Landscape
Recent Developments in the Tendinopathy Market
In October 2025, Causeway Therapeutics announced positive Phase II topline data for TenoMiR (CWT-001) in elbow tendinopathy. Correctly injected patients showed significant improvements in pain, function, and tendon structure.
TenoMiR (CWT-001) is an investigational first-in-class microRNA-based therapy designed to restore microRNA-29a levels in injured tendon tissue.
Causeway Therapeutics plans to initiate a Phase III trial of TenoMiR in lateral epicondylitis and a Phase II study in rotator cuff tendinopathy.
In a study involving 90 patients receiving the target dose of TenoMiR or placebo, the therapy demonstrated significant reductions in pain and improvements in upper limb and elbow-specific function at 14, 28, and 90 days.
VergenixSTR, developed by CollPlant, is approved in the EU for treating tendinopathy in various tendons, including elbow, rotator cuff, patellar, Achilles, and hand tendons.
What is Tendinopathy?
Tendinopathy is a chronic musculoskeletal disorder characterized by tendon pain, functional limitation, and structural abnormalities including collagen disorganization, neovascularization, and failed tendon healing. Commonly affected tendons include the Achilles tendon, patellar tendon, rotator cuff, elbow epicondyles, and gluteal tendons. The condition is associated with repetitive mechanical overload, aging, obesity, diabetes, sports injuries, and occupational stress. Diagnosis is primarily clinical and supported by imaging techniques such as ultrasound and MRI in uncertain cases.
Tendinopathy Epidemiology Segmentation
The Tendinopathy epidemiology section provides insights into the historical and current Tendinopathy patient pool and forecasted trends for the 7MM. The Tendinopathy market report proffers epidemiological analysis for the study period 2022–2036 segmented into:
Total Incident Cases of Tendinopathy
Gender-specific Cases of Tendinopathy
Age-specific Cases of Tendinopathy
Region-specific Cases of Tendinopathy
Total Treated Cases of Tendinopathy
Scope of the Tendinopathy Market Report
Therapeutic Assessment: Tendinopathy current marketed and emerging therapies
Tendinopathy Market Dynamics: Key Market Forecast Assumptions of Emerging Tendinopathy Drugs and Market Outlook
Key Companies: Causeway Therapeutics, New York R&D Center for Translational Medicine and Therapeutics, CollPlant, and others
Key Therapies: TenoMiR (CWT-001), TenoGen, PRP Therapy, VergenixSTR, ESWT, Glyceryl Trinitrate, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Tendinopathy Market Access and Reimbursement
To know more about Tendinopathy companies working in the treatment market, visit @ Tendinopathy Clinical Trials and Therapeutic Assessment
Table of Contents
Tendinopathy Market Report Introduction
Executive Summary for Tendinopathy
SWOT Analysis of Tendinopathy
Tendinopathy Patient Share (%) Overview at a Glance
Tendinopathy Market Overview at a Glance
Tendinopathy Background and Overview
Tendinopathy Epidemiology and Patient Population
Country-Specific Patient Population of Tendinopathy
Tendinopathy Current Treatment and Medical Practices
Tendinopathy Unmet Needs
Tendinopathy Emerging Therapies
Tendinopathy Market Outlook
Country-Wise Tendinopathy Market Analysis (2022–2036)
Tendinopathy Market Access and Reimbursement of Therapies
Tendinopathy Market Drivers
Tendinopathy Market Barriers
Tendinopathy Appendix
Tendinopathy Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: https://www.delveinsight.com/consulting/due-diligence-servicesCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
